ASCO 2015 | Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer

Eleni Efstathiou

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer.

Share this video  
Related videos
2:00
Personalized medicine: surgery
John Gore
4:14
Evaluation of costs associated with AEs in urothelial cancer patients
Petros Grivas
3:39
TGF-β/EMT gene signature in low-responders to pembrolizumab
Petros Grivas
1:28
Meaningful, patient-centered research
John Gore
2:47
Rucaparib for urothelial carcinoma: the ATLAS study
Petros Grivas
Genitourinary Cancer, Genitourinary Cancer, Prostate Cancer
Abiraterone, Leuprolide acetate
ASCO 2015
Interview
30th May 2015
More from Eleni Efstathiou
Abiraterone: a step forward in the treatment of prostate cancer
Making advances in prostate cancer
Trial of LHRHa, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals